The application's broad, long-term objectives are to discover a blood test for early detection of ovarian cancer that will reduce ovarian cancer mortality through regular testing of targeted populations. Initially these populations would include women at high risk due to family history and/or presence of a BRCA1or BRCA2 mutation within the family, and all postmenopausal women where the incidence of disease is highest. The test requires high sensitivity for early stage disease and very high specificity so that few false positive tests will occur for each true positive test.
The specific aims are 1) to discover high probability candidate biomarkers through proteomic analysis of biofluids from three sources a) ovarian cyst fluid from benign and malignant ovarian disease, b) conditioned media from fresh sliced washed normal and malignant tissue, and c) conditioned media from phenocopy model fallopian tube systems, 2) discover high probability candidate biomarkers from genomic analysis using Affymetrix arrays of normal fallopian tube, normal ovarian, and ovarian malignant tissue lysate filtered by a comprehensive list of secreted proteins from ovarian tissue (secretome), 3) prioritize candidate biomarkers for verification by analysis of pathways from ovarian cancer pathogenesis, 4) construct mass spectrometric assays for the top 50 candidates and measure these candidates in plasma from 100 cases and 100 benign controls, and in longitudinal plasma in cases prior to clinical detection, and in controls from an ovarian cancer screening trial, and 5) determine which candidates have earliest sensitivity by estimating the change-point (if any) at which the candidate rises significantly above baseline. The five best candidates will form a biomarker panel for further testing and refinement, outside the scope of this application, in the biorepositories of larger scale screening studies.

Public Health Relevance

to public health: This research may lead to a screening test for ovarian cancer with subsequent reduction in ovarian cancer mortality. Ovarian cancer is highly curable if discovered while in early stage disease when it is confined to the ovaries. A screening test may lead to fewer ovarian cancer cases being discovered in late stage disease and thus may reduce the rate at which women die of ovarian cancer.

National Institute of Health (NIH)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Patriotis, Christos F
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Massachusetts General Hospital
United States
Zip Code
Labidi-Galy, S I; Clauss, A; Ng, V et al. (2015) Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors. Oncogene 34:373-83
Dunn, Gavin P; Cheung, Hiu Wing; Agarwalla, Pankaj K et al. (2014) In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene. Proc Natl Acad Sci U S A 111:1102-7
Skates, Steven J (2014) A statistical challenge: developing tests for biomarker utility specific to the intended use. J Natl Cancer Inst 106:dju076
Emori, Megan M; Drapkin, Ronny (2014) The hormonal composition of follicular fluid and its implications for ovarian cancer pathogenesis. Reprod Biol Endocrinol 12:60
Karst, Alison M; Jones, Paul M; Vena, Natalie et al. (2014) Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers. Cancer Res 74:1141-52
Holman, Laura L; Lu, Karen H; Bast Jr, Robert C et al. (2014) Risk perception, worry, and test acceptance in average-risk women who undergo ovarian cancer screening. Am J Obstet Gynecol 210:257.e1-6
Perets, Ruth; Wyant, Gregory A; Muto, Katherine W et al. (2013) Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell 24:751-65
Dubeau, L; Drapkin, R (2013) Coming into focus: the nonovarian origins of ovarian cancer. Ann Oncol 24 Suppl 8:viii28-viii35
Wei, Wei; Mok, Samuel C; Oliva, Esther et al. (2013) FGF18 as a prognostic and therapeutic biomarker in ovarian cancer. J Clin Invest 123:4435-48
O'Neal, Ryan L; Nam, Ki Taek; LaFleur, Bonnie J et al. (2013) Human epididymis protein 4 is up-regulated in gastric and pancreatic adenocarcinomas. Hum Pathol 44:734-42

Showing the most recent 10 out of 19 publications